SCHEMBL19684931

SCHEMBL19684931

CCCCOc1cc(C)cc2c1CN(C(=O)OC(C)(C)C)CCO2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.39
KDR P35968 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.37
USP2 O75604 1/20 0.37
PIK3CD O00329 1/20 0.37
GPR119 Q8TDV5 3/20 0.36
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
ESR2 Q92731 1/20 0.35
KDM4E B2RXH2 2/20 0.35
NPC1 O15118 1/20 0.35
GLA P06280 1/20 0.35
HPGD P15428 1/20 0.35
RAB9A P51151 1/20 0.35
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19684696 0.89 RIPK1 (0.39) SMN1; SMN2USP2PIK3CDGPR119PRMT5
SCHEMBL19684711 0.89 PIK3CD (0.36) SMN1; SMN2USP2PIK3CDGPR119PRMT5
SCHEMBL19684747 0.87 PDE4D (0.37) SMN1; SMN2USP2PIK3CDGPR119PRMT5
SCHEMBL19684713 0.87 RIPK1 (0.39) SMN1; SMN2USP2PIK3CDGPR119PRMT5
SCHEMBL19684712 0.87 SMN1; SMN2 (0.35) SMN1; SMN2USP2PIK3CDGPR119PRMT5
SCHEMBL19667616 0.83 TLR9 (0.41) CSF1RKDRSMN1; SMN2KDM4EHPGD
SCHEMBL17462518 0.81 USP2 (0.44) SMN1; SMN2USP2PIK3CDGPR119ESR2
SCHEMBL19667597 0.80 USP2 (0.43) SMN1; SMN2USP2PIK3CDGPR119PRMT5
SCHEMBL17462516 0.74 ESR2 (0.45) SMN1; SMN2USP2PIK3CDGPR119PRMT5
SCHEMBL17462514 0.73 USP2 (0.41) SMN1; SMN2USP2PIK3CDGPR119PRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2017-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS DUT, NCL, TYMP CSF1R 4098/4885KDR 2465/4885SMN1; SMN2 1375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.